Success Stories: A Chinese Research Fellow in Maryland in the Field of Pharmacology Obtains EB-1A Petition Approval Just 18 Days after Filing
Client’s Testimonial:
“Thank you very much for the great news. I will definitely write a recommendation for your firm”
On Jan 21th, 2017, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Pharmacology (Approval Notice).
General Field: Pharmacology
Position at the Time of Case Filing: Research Fellow
Country of Origin: China
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Maryland
Approval Notice Date: Jan 21th, 2017
Processing Time: 18 days (Premium Processing requested)
Case Summary:
Just 18 days after North America Immigration Law Group (WeGreened.com) filed an EB-1A (Alien of Extraordinary Ability) petition on behalf of a research fellow in Maryland, the USCIS approved his case. This prompt adjudication was a result of Premium Processing (PP), a paid service offered by the USCIS which allows petitioners to have action taken on their cases within 15 calendar days. Nonetheless, there is no denying that our diligent efforts in the demonstration of our client’s skills and research set the platform for this accomplishment. These are some of the main areas we focused on while building his EB-1A petition:
- We incorporated recommendation letters signed by other experts in the field in order to fortify his case. According to one of the experts: “[Client’s] academic experience had provided him with a valuable skillset that he continues to apply in his ongoing efforts to advance the pharmacology field”.
- The petition packet featured our client’s exemplary publication record. At the time of filing, he had already published 8 peer-reviewed scientific articles, all of which made an appearance in some of the most prestigious, high impact journals in his field.
- We also highlighted his citation count and peer review record. At the time of filing, our client’s work had gathered 60 citations and he had conducted at least 120 peer reviews.
- One of the major highlights of our client’s petition was his voluminous research portfolio. We demonstrated to the USCIS how our client’s research addresses some of the United States’ most pressing issues in understanding the treatment of cancer, diabetes, and cardiac amyloidosis.
We congratulate our client for securing an EB-1A approval notice and we wish him the best as he continues to progress the field of pharmacology in the US.

